<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99006">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01711658</url>
  </required_header>
  <id_info>
    <org_study_id>RF-3501</org_study_id>
    <secondary_id>LAP116153</secondary_id>
    <nct_id>NCT01711658</nct_id>
  </id_info>
  <brief_title>TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.</brief_title>
  <acronym>TRYHARD</acronym>
  <official_title>TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE: This trial is studying if and how well lapatinib adds to the effectiveness of
      radiation therapy plus cisplatin in patients who have head and neck cancer that is not
      related to the HPV virus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-Free survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time from randomization until local, regional, or distant disease progression, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time from randomization until development of distant metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Participants are followed for up to 17 months from the start of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Data is collected during protocol treatment and 30 days after whether or not related to the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with planned treatment</measure>
    <time_frame>maintenance therapy is 12 months and could be different for each patient.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional failure</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time from randomization until local-regional recurrence or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Status Scale for Head &amp; Neck Cancer.</measure>
    <time_frame>3 months, 1 year, and 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy - Head &amp; Neck.</measure>
    <time_frame>3 months, 1 year, and 2 years.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of Michigan Xerostomia-Related Quality of Life Scale.</measure>
    <time_frame>3 months, 1 year, and 2 years.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HER2, EGFR, EMT as biomarkers of response.</measure>
    <time_frame>End of Study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time from randomization until death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Non-HPV Locally Advanced Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation therapy + cisplatin + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation therapy + cisplatin + lapatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity modulated radiation therapy</intervention_name>
    <description>70 Gy in 2 Gy fractions</description>
    <arm_group_label>Radiation therapy + cisplatin + placebo</arm_group_label>
    <arm_group_label>Radiation therapy + cisplatin + lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>100 mg/m2 on days 8 and 29</description>
    <arm_group_label>Radiation therapy + cisplatin + placebo</arm_group_label>
    <arm_group_label>Radiation therapy + cisplatin + lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 12 months</description>
    <arm_group_label>Radiation therapy + cisplatin + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 12 months</description>
    <arm_group_label>Radiation therapy + cisplatin + lapatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients must have histologically or cytologically confirmed Squamous Cell  Cancer of
             the oropharynx, hypopharynx or larynx (For patients with oropharynx primary, the
             tumor must be negative for p16 by immunohistochemistry).

          -  Patients with selected Stage III or IV disease (T2 N2-3 M0, T3-4 any N M0, T1 N2b,
             N2c or N3p16 negative oropharynx cancer or T1-2 any N hypopharynx cancer) including
             no distant metastases.

          -  History/Physical examination by a Radiation Oncologist and Medical oncologist prior
             to entering the study.

          -  Examination by an ENT or Head &amp; Neck Surgeon including laryngopharyngoscopy prior to
             entering the study.

          -  Patients must have a chest CT scan, or PET/CT scan to rule out metastatic disease

          -  Patients must have a CT scan, MRI, or PET/CT scan of the tumor site and neck nodes
             prior to entering the study.

          -  Patients must have an EKG and ECHO or MUGA scan prior to entering the study.

          -  Patients must have Zubrod Performance Status of 0-1.

          -  Patients must be ≥ 18 years of age.

          -  Patients must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3

               -  Platelets ≥ 100,000 cells/mm3

               -  Hemoglobin ≥ 8.0 g/dl

               -  Serum creatinine &lt; 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min

               -  Total bilirubin &lt; 2 x the institutional upper limit of normal

               -  AST or ALT ≤  3 x the institutional upper limit of normal

          -  Patient must have magnesium, calcium, glucose, potassium and sodium levels within
             normal limits

          -  Women of childbearing potential must have a negative pregnancy test prior to
             registration.

          -  Patients of reproductive potential must practice effective contraception while on
             study and for at least 60 calendar days following treatment.

          -  All patients must sign an informed consent prior to enrollment.

          -  Patients must comply with the treatment plan and follow-up schedule.

        Exclusion criteria:

          -  Patients with simultaneous primaries or bilateral tumors.

          -  Patients who have had gross total excision of the primary tumor.

          -  Patients with initial surgical treatment, radical or modified neck dissection.

          -  Patients who received prior systemic chemotherapy for the study cancer.

          -  Patients who received prior radiotherapy to the region of the study cancer that would
             result in overlap of radiation therapy fields.

          -  Patients with primary tumor of oral cavity, nasopharynx, sinuses or salivary glands.

          -  Prior allergic reaction to the study drugs.

          -  Patients who have had prior therapy that specifically and directly targets the
             EGFR/HER2 pathway.

          -  Patients who have current active hepatic or biliary disease (with exception of
             patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver
             disease per investigator assessment);

          -  Pregnant women or sexually active patients not willing or able to use medically
             acceptable forms of contraceptive method while on treatment.

          -  Patients with severe, active co-morbidity, defined as follows:

               -  Uncontrolled cardiac disease, such as uncontrolled hypertension, unstable
                  angina, and/or congestive heart failure requiring hospitalization within the
                  last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Left ventricular ejection fraction &lt; 45%

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of registration

               -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within 30 calendar days
                  prior to registration

               -  Hepatic insufficiency resulting in clinical jaundice and/or Coagulation defects

               -  Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stuart Wong, MD</last_name>
    <email>swong@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - University of Alabama at Birmingham C</last_name>
      <phone>205-934-0309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nayana L. Vora, MB, BS</last_name>
      <phone>626-359-8111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loren Mell, MD</last_name>
      <email>lmell@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiological Associates - Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Jones</last_name>
      <email>jonesc@radiological.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sue S Yom, MD, PhD</last_name>
      <email>yoms@radonc.ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Stanford Cancer Center</last_name>
      <phone>650-498-7061</phone>
      <email>cctoffice@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan J. Beitler</last_name>
      <phone>404-686-4411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center at University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shiao Y. Woo</last_name>
      <phone>502-562-4158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuhchyau Chen, MD</last_name>
      <email>yuhchyau_chen@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yao</last_name>
      <email>min.yao@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura L Gillison, MD, PhD</last_name>
      <email>maura.gillison@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrance Herman, MD</last_name>
      <email>terence-herman@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center Buckingham</name>
      <address>
        <city>Furlong</city>
        <state>Pennsylvania</state>
        <zip>18925</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Galloway, MD</last_name>
      <email>thomas.galloway@fccc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical School</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Yordy, MD, PhD</last_name>
      <email>john.yordy@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Gunn, MD</last_name>
      <email>gbgunn@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul M. Harari</last_name>
      <phone>608-263-8500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Wong, MD</last_name>
      <email>swong@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill Cancer Centre at McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Shenouda</last_name>
      <phone>514-398-1444</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Harrington K. et al. Phase II study of oral Lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 28:15s, 2010 suppl. Abstract 5505. GSK study 884</citation>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
